Although biofeedback therapy is effective in the short-term management of dyssynergic defecation, its long-term effi cacy is unknown. Our aim was to compare the 1-year outcome of biofeedback (manometric-assisted pelvic relaxation and simulated defecation training) with standard therapy (diet, exercise, laxatives) in patients who completed 3 months of either therapy.
INTRODUCTION
About one third of patients with chronic constipation have an evacuation disorder, and most have dyssynergic defecation ( 1 -4 ) . Also known as anismus ( 5 ) or pelvic fl oor dyssynergia ( 6 ) , dyssynergia is characterized by a failure of the abdominal, rectal, pelvic fl oor, and anal sphincter muscles to eff ectively coordinate and complete the process of defecation ( 6 -10 ) , Consequently, these patients complain of excessive straining, incomplete evacuation, and hard stools together with infrequent stooling ( 3, 4, 11 ) , and about 40 % use digital maneuvers to assist defecation ( 11 ) . Most of them are refractory to traditional approaches of management of constipation. Th e impaired propulsion of stool from the rectum, paradoxical anal contraction, or inadequate anal relaxation together with impaired rectal sensation or a combination of these mechanisms leads to dyssynergic defecation ( 7, 9, 10 ) .
Recently, three randomized controlled trials have concluded that biofeedback therapy is superior to sham feedback or standard therapy ( 12 ) or laxatives ( 13 ) or diazepam ( 14 ) in the management of patients with dyssynergic defecation. However, these trials were short term (3 months), whereas constipation with dyssynergic defecation is a chronic disorder with a prevalence of symptoms of at least 2 years ( 11, 13 ) . Whether biofeedback therapy is eff ective in the long-term management of patients with dyssynergic defecation has not been systematically assessed.
In two uncontrolled long-term studies, biofeedback therapy was felt to improve symptoms ( 15, 16 ) . In the only other long-term controlled study, patients with normal colonic transit and dyssynergia were found to show greater improvement in bowel function aft er biofeedback but not aft er polyethylene glycol ( 13 ) . However, a majority of patients with dyssynergic defecation have coexisting slow transit constipation ( 3, 7, 8, 17 ) . Th us, whether biofeedback
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therapy is eff ective in the long-term management of all subjects with dyssynergic defecation, irrespective of their colonic transit is not known.
In this study, we hypothesized that patients with dyssynergic defecation who receive biofeedback therapy will show greater longterm improvement in bowel symptoms and in colonic and anorectal physiology when compared with those who receive standard therapy. Our aim was to prospectively compare the 1-year symptomatic and physiologic outcome of biofeedback therapy with standard therapy in patients with constipation and dyssynergic defecation who completed 3 months of either therapy. Specifi cally, we tested whether subjects who received biofeedback therapy were more likely to show an increase in the number of complete spontaneous bowel movements (CSBMs) and to correct a dyssynergic pattern of defecation when compared with those who received standard therapy.
METHODS
We recruited subjects with chronic constipation who had failed routine management of constipation ( > 1 year) and fulfi lled Rome II criteria for functional constipation ( 18 ) . In addition, all subjects fulfi lled the following criteria for dyssynergic defecation: they showed a dyssynergic pattern of defecation during attempted defecation ( 13 ) , and either had prolonged diffi culty with expelling a 50-ml water-fi lled balloon ( > 1 min) or prolonged delay ( > 20 % marker retention) in colonic transit time ( 6, 8, 12 ) . Th ey were also required to have no evidence of structural or metabolic diseases that could cause constipation, as assessed by colonoscopy / barium enema and routine hematological, biochemical, and thyroid function tests. Patients taking constipating drugs, for example opioids, were excluded or were asked to discontinue the drug 2 weeks before enrollment. Other exclusion criteria included: previous gastrointestinal, spinal, or pelvic surgery except cholecystectomy, hysterectomy, or appendectomy, alternating constipation and diarrhea rectal prolapse, anal fi ssure, neurologic diseases such as multiple sclerosis, stroke, or spinal injury, severe cardiac or renal disease, impaired cognizance (mini-mental score < 15), pregnancy, and legal blindness.
Subjects were randomized using the permuted blocks method with 1:1 assignment into the two study groups (Biofeedback and Standard). Random numbers generated in advance were placed into sequentially numbered opaque envelopes, sealed and used for subject assignment. Although the therapist and patient could not be blinded, the investigators performing the subjective and manometry analyses were blinded to the patient assignment or earlier data. Standard protocols were used for each group to ensure that all patients received similar general guidelines for management of their constipation.
We assessed several objective and subjective outcome measures at baseline and aft er treatment because a diagnosis of dyssynergic defecation requires both symptomatic and physiological parameters ( 6, 8, 10 ) . Th ese included anorectal physiology, balloon expulsion test ( 8, 19, 20 ) , and colonic transit study in which three diff erent shaped radioopaque markers (Sitzmark, Konsyl Pharmaceuticals Fort Worth, TX) were administered on 3 consecutive days and a plain abdomen x-ray was taken on day 6 ( 12 ) . All subjects were required to maintain a prospective stool diary, starting 1 week before enrollment in which they recorded the time, consistency (Bristol stool scale; type 1 = hard pellets and 7 = watery stools), straining eff ort (1 = normal, 2 = moderately excessive, 3 = severe) of each bowel movement and whether a bowel movement was complete, and whether they needed digital assistance ( 12 ) . Also, they rated the overall satisfaction with bowel function on a 100-mm visual analog scale (VAS). Th e study was approved by the Institutional Review Board and all participants gave written informed consent.
Standard treatment
During an initial visit, a gastroenterologist, nurse therapist, and dietitian provided advice regarding bowel habits, exercise, laxatives, dietary fiber and fluid intake, and timed-toilet training ( 12 ) . This was reinforced by the nurse therapist during follow-up visits.
All patients were advised to attempt bowel movement for 5 min, twice a day, 30 min aft er eating, irrespective of their urge to defecate. Th e nurse therapist taught subjects how to improve their push eff ort by using postural and diaphragmatic breathing techniques, and instructed them to practice these maneuvers at home for 15 min, three times a day ( 12 ) . Magnesium gluconate (Magonate 500 mg, Fleming & Company, St Louis, MO) 2 -4 tablets daily was recommended daily as the standard laxative, and subjects were instructed to titrate the dose. All subjects were advised to refrain from using digital maneuvers to assist defecation, and if used its use was recorded. Patients having no bowel movement for 48 h were instructed to use one glycerin suppository, then aft er 72 h, a tap water enema, and aft er 96 h, two Bisacodyl tablets orally (rescue laxatives). Th e dietitian advised subjects to consume a balanced, adequate calorie diet, increase fruit and vegetable intake to fi ve servings per day, and consume 25 g of dietary fi ber from natural food sources daily. Aft er completing their initial treatment for 3 months (short-term therapy), subjects were invited to enroll in the long-term phase of this study and to return for three follow-up visits at 3-month intervals with the last scheduled visit at 1 year aft er starting therapy. During these 1 h follow-up visits, their symptoms and bowel habits were assessed and additional advice was provided as needed. All subjects were required to maintain a 1-week stool diary before each visit, which was used for symptom analysis. Manometric and colonic transit measurements and balloon expulsion tests were performed at the end of 1 year.
Biofeedback treatment
In addition to receiving the instructions described under standard therapy, subjects randomized to biofeedback therapy had biofeedback training sessions by a nurse therapist. Biofeedback therapy consisted of placing a solid state manometry probe into the rectum (Koningsberg Instruments, Pasadena, CA), and using soft ware (Gaeltec Ltd. Dunvegan, Isle of Skye) for displaying the manometric data. Biofeedback therapy consisted of Rao et al.
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three components. Th e goal of rectoanal coordination was to increase the push eff ort as refl ected by a rise in intra-abdominal / intrarectal pressures and synchronized with anal relaxation as refl ected by a decrease in anal sphincter pressure. Subjects were asked to sit on a commode and watch the manometric tracings on a computer monitor, and received training using visual and verbal feedback techniques ( 6, 12 ) . Th e goal of simulated defecation training was to train subjects over three consecutive trials to expel a silicone-fi lled artifi cial stool-FECOM. Th e subjects ' posture and breathing techniques were continuously monitored and appropriate advice and feedback was provided to improve defecatory eff ort. Patients with impaired rectal sensation received sensory conditioning by repeated infl ations / defl ations of a rectal balloon ( 6, 12 ) . Aft er completing 3 months (short-term therapy), subjects who agreed to participate in the long-term phase of our study were asked to return for three follow-up visits at 3-month intervals with the last visit scheduled at 1 year. During these visits, they received general advice and biofeedback therapy. Bowel symptoms and stool patterns were assessed from a prospectively maintained 1-week stool diary before each visit. Manometric and colonic transit measurements and balloon expulsion tests were repeated at 1 year.
Data analysis and outcome measures
Th e primary outcome measure was the number of CSBMs per week. A spontaneous bowel movement was defi ned as a bowel movement that occurred naturally or without the use of rescue laxatives, suppositories, or enemas within the previous 24 h. A CSBM was defi ned as a spontaneous bowel movement reported on a stool diary without a feeling of incomplete evacuation. Secondary outcome measures included the global bowel satisfaction as recorded on VAS, stool frequency, stool consistency, straining eff ort, proportion of patients needing digital assistance for stooling, and a laxative consumption score per week [none = no laxatives, Type I = high fi ber diet ± bran and stool soft eners, Type II = oral laxatives [magnesium oxide, 17 g polyethylene glycol (Miralax Braintree Labs, MA), Type III = stimulants (Bisacodyl), Type IV = enemas, suppositories, magnesium citrate, 236 g polyethylene glycol solutions (Golytely Braintree Labs, MA)]. Th e physiologic outcome measures included the presence of dyssynergia during attempted defecation, balloon expulsion time, anal residual pressure, % anal relaxation, intrarectal pressure, and defecation index during attempted defecation ( 19, 20 ) , thresholds for fi rst perception and urge to defecate ( 20 ) , and the proportion of subjects with slow colonic transit time. All subjects who signed a consent form and agreed to participate in the long-term study irrespective of whether they dropped out or they completed the study were included in the data analyses and an intention to treat analyses were performed.
Statistical analysis
Th e primary outcome measure was the number of CSBM per week, and this was analyzed using repeated-measure negative binomial regression analysis. Th e number of stools and CBMs per week and the balloon expulsion time were also analyzed using negative binomial regression. As these analyses involve log-transformed data, the results are expressed as means with their asymmetrical mean−s.e.m. and mean + s. e.m. Mixed-model analysis of variances were used for assessment of the bowel satisfaction VAS, the stool consistency and stool strain scores, and the physiological anorectal manometric data. Th ese quantitative data are expressed as mean ± s.e.m. Th e use of laxatives and of digital assistance and the presence of slow colonic transit were analyzed using exact probabilities from Fisher ' s and McNemar ' s tests. Th e Fisher ' s test was also used for analysis of the proportion of subjects with dyssynergia at the 1-year assessment. Th ese data are expressed as subject counts. For the six subjects in the standard therapy arm who did not complete the 1-year assessment, the results from their previous assessments were carried forward to 1 year. We compared the data for baseline vs. post-treatment at 1 year for each intervention as well as testing for baseline vs. post-treatment diff erences between the two study arms.
Count data that detail the number of events over a certain period of time (e.g., number of CSBMs over 7 days) or the time delay to an event (e.g., number of seconds needed to expel a balloon) oft en tend to have distributions that are highly skewed toward the right with many zeros. In such circumstances, analyses based on the Gaussian (normal) distribution are inappropriate. Hence, we have analyzed our count data with repeated-measures regression models that are based on the negative binomial distribution, involving estimation of an additional dispersion parameter that allows for inequality of mean and variance and for correlation among the observations.
RESULTS

Subject demographics
Fift y-two subjects with dyssynergic defecation were randomized, of whom forty-four subjects (21 in biofeedback, 23 in standard) completed the initial phase of treatment (3 months). Th e outcome of this phase of our study has been reported earlier ( 12 ) . Of the 21 patients who completed the short-term biofeedback treatment and were eligible for the long-term study, 13 (m / f = 1 / 12, mean age = 48 years) elected to participate in the long-term assessment, and all of these subjects completed 1 year of treatment, whereas 8 subjects declined to participate, although 7 / 8 had improved ( Figure 1 ) . Th e reasons for declining further participation were personal, including transportation issues (4), relocation (1), other medical problems (2) and hip surgery (1) . Of the 23 subjects who completed the standard treatment, 10 declined [personal reasons (7), relocation (1), pelvic surgery (1), medical problems (1)], and 7 / 10 had improved and 3 / 10 had failed therapy. Th e remaining 13 subjects (m / f = 2 / 11, mean age = 45 years) elected to participate in the longterm study. Among these, six subjects failed standard therapy with one requiring colectomy at 6 months and fi ve choosing behavioral therapy between 6 and 9 months aft er initial enrollment. Seven subjects completed 1 year of standard therapy. All 13 subjects who agreed to participate in the long-term study of standard therapy were included in the intention to treat analysis ( Figure 1 ).
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Symptom profi les
Th e baseline bowel symptom profi les including stool frequency, stool consistency, and straining eff ort were comparable and similar between the two groups, including the percentage of subjects needing digital assistance to defecate ( Table 1 ) .
Outcome measures
Primary outcome measure. Subjects who were randomized to biofeedback therapy showed a signifi cant increase in the number of CSBMs per week when compared with the baseline period ( P < 0.001) and when compared with the standard group ( P < 0.002), whereas there was no change in the standard group ( Figure 2 ) . Secondary symptomatic outcome measures. Th e mean number of bowel movements per week and the mean number of complete bowel movements per week also increased significantly in the biofeedback group when compared with standard group ( P = 0.005) and baseline ( P = 0.0003) ( Table 1 ) . Th e bowel satisfaction score increased signifi cantly ( P < 0.0001) aft er biofeedback therapy and aft er standard therapy ( P < 0.001) when compared with baseline ( Table 1 ) . Although subjects receiving biofeedback reported more improvement, the diff erence was not Rao et al.
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time decreased signifi cantly in subjects who received biofeedback when compared with their baseline ( P < 0.0001), but not in the standard group ( P = 0.12) ( Figure 4 ). Also, the balloon expulsion time improved signifi cantly in those who received biofeedback when compared with the standard group ( P = 0.0009). Th e anal residual pressure decreased ( P < 0.0001), the intrarectal pressure increased ( P < 0.01), and defecation index increased signifi cantly ( P < 0.0001) in the biofeedback group when compared with baseline, but was unchanged in the standard treatment group ( Table 2 ) . Also, all of these parameters improved signifi cantly in the biofeedback group ( Table 2 ) , when compared with those who received standard therapy.
In the biofeedback group, the threshold for fi rst sensory perception decreased signifi cantly at 1 year when compared with baseline ( P = 0.01) ( Table 2 ). Th ere was no diff erence in other sensory thresholds between the two groups. At baseline, 54 % (7 / 13) and aft er treatment 7.7 % (1 / 13) of subjects who received biofeedback had slow colonic transit ( P = 0.01), when compared with 54 % (7 / 13) and 30 % (4 / 13), respectively ( P = 0.09) with standard therapy ( Table 2 ).
DISCUSSION
In this study, we found that subjects who were treated with biofeedback therapy showed a sustained improvement in bowel symptoms, as refl ected by a signifi cant increase in the number of CSBMs per week (the primary outcome measure) when compared with baseline and when compared with standard therapy. Also, these subjects showed a greater increase in the total number of bowel movements and were more likely to discontinue the use of digital maneuvers than subjects who received standard treatment. Th us, our longterm randomized controlled trial revealed that at 1 year, biofeedback therapy was more likely to restore normal bowel function in subjects with chronic constipation and dyssynergic defecation than standard therapy.
In parallel with the symptomatic improvement, we also observed a signifi cant improvement in colonic and anorectal function as revealed by measurements of colonic transit and anorectal physiology. Aft er biofeedback, colonic transit time improved signifi cant. Th ere was no change in the mean straining eff ort score in both groups ( Table 1 ) .
Th ere was a non-signifi cant trend toward soft er stools in both the biofeedback (3.7 ± 0.3 vs. 4.0 ± 0.3, P = 0.4) and standard (3.2 ± 0.3 vs. 3.6 ± 0.3, P = 0.4) therapy groups, but there was no diff erence between groups ( P = 0.4). Th e laxative usage did not signifi cantly change in either group. All subjects were using a Type I or Type II laxative at baseline. A Type III or Type IV laxative was used by 1 / 13 and 3 / 13 subjects randomized to biofeedback therapy, both at baseline and at 1 year ( P = 1.0). Similarly, 2 / 13 used a Type III laxative and 1 / 13 subjects used a Type IV laxative at baseline, and 1 / 13 and 2 / 13 subjects, respectively, at 1 year in the standard therapy group. Approximately 30 % of subjects in the biofeedback group discontinued all laxative usage, whereas none of the subjects in the standard group stopped using laxatives in 1 year. A need for digital assistance with stooling lessened signifi cantly ( P = 0.05) in the biofeedback group but not in the standard group ( Table 1 ) .
Physiological outcome measures
Th e dyssynergia pattern was corrected in 12 / 13 subjects who received biofeedback, and in none of the subjects who received standard treatment ( Figure 3 ). Biofeedback was superior to baseline and standard treatment ( P < 0.0001). Th e balloon expulsion 
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signifi cantly and normalized in almost all subjects with co-existing slow transit constipation, but mean transit time did not signifi cantly improve in subjects aft er standard therapy. Th e lack of statistical difference between the two treatment arms could be due to a Type II error. At baseline, all subjects showed a dyssynergic pattern of defecation during an attempted defecation. Aft er treatment, all subjects randomized to standard treatment continued to exhibit dyssynergia, whereas 92 % of subjects who received biofeedback therapy showed that the dyssynergic pattern of defecation was corrected. Likewise, other manometric indices that refl ect a coordinated bowel movement such as the defecation index, and the time taken to expel a balloon also improved signifi cantly in the biofeedback group but were unchanged in the standard group. Th ese fi ndings confi rm earlier observations ( 8, 11, 13 ) that dyssynergic defecation is a chronic disorder and will persist unless a behavioral intervention is instituted to correct the underlying dysfunction. Also, biofeedback therapy is eff ective in reversing these dysfunctions. As all patients received a similar degree of attention and advice regarding coping strategies, it seems that the clinical improvement in subjects who received biofeedback therapy was mainly achieved by modifying the underlying physiological dysfunction. In contrast, the standard therapy group failed to show any improvement in a range of primary and secondary outcome measures and had many dropouts. Th e lack of any change in anorectal function aft er standard therapy suggests that treatment with laxatives, exercise, diet, and advice alone was unlikely to correct the chronic bowel problem.
Th e global bowel satisfaction score improved aft er biofeedback as well as aft er standard therapy when compared with baseline. Th is fi nding further confi rms our earlier study ( 12 ) and suggests that carefully monitored therapy with coping strategies may improve satisfaction with bowel symptoms in some patients with chronic bowel problems, but may not produce real and eff ective change in bowel function. Th is observation underscores the need for performing randomized controlled trails and for using objective measures of assessing bowel function; reliance on subjective measures such as global satisfaction as a sole measure of improvement may be inadequate, as it can be infl uenced by other factors such as a desire to please the investigators or by their overall wellbeing, and not necessarily by their bowel function ( 21, 22 ) .
Our fi ndings extend and confi rm the only other long-term controlled study (13) , but there were methodological diff erences that merit discussion. We included all subjects with dyssynergic defecation, whereas the earlier study excluded patients with dyssynergia and coexisting slow transit constipation. As nearly 60 % of patients with dyssynergic defecation have coexisting slow transit constipation ( 3, 7, 17 ) , we believe that our study population represents the broad group of dyssynergic subjects who are commonly encountered in clinical practice. Furthermore, colonic transit time normalized in almost all subjects with dyssynergic defecation aft er biofeedback therapy. Th is reaffi rms that the transit abnormalities were secondary to outlet dysfunction and that dyssynergics with slow transit will respond favorably to biofeedback therapy. Also, in our study, the biofeedback and the standard therapy were administered by a nurse, under supervision of a physician, whereas, in their study two separate physicians, one a gastroenterologist and another a skilled biofeedback therapist provided all of the therapy including laxatives to the biofeedback group, whereas another physician provided laxatives to the control group raising concerns for equitable management. Finally, aft er 3 months of treatment, they told all patients who received biofeedback, irrespective of their outcome that they had improved. Although motivating patients is important, doing so by elevating patient ' s expectations especially in a disorder with signifi cant psychological comorbidity ( 23 ) could bias the clinical outcome, especially when the primary outcome measure was the subjects ' rating of symptom improvement. No such advice was given to our patients. Nonetheless, both studies found that biofeedback therapy was superior to laxatives in the long term.
Th e limitations of our study include the smaller sample size. Our screen failure and drop out rate is similar to those reported in earlier biofeedback studies and refl ects issues with recruitment and retention of subjects in a long-term labor-intensive clinical trial ( 12, 14, 24 ) . However, approximately equal number of subjects agreed to participate in both arms of the long-term trial, and a similar number declined aft er completion of the initial 3 months treatment. Th e refusal to participate in the long-term study was not because of a failure to respond to treatment in either group, but largely due to personal reasons or comorbidity issues. In the standard therapy group, 6 / 13 (48 % ) subjects failed long-term treatment. One subject developed signifi cant worsening of symptoms and elected to have a colectomy, and fi ve others felt that their symptoms had not improved, usually aft er another few months of long-term therapy and declined further participation. Th ese fi ve subjects successfully completed biofeedback therapy outside the clinical trial. In contrast, all 13 subjects assigned to the biofeedback group completed 1 year of treatment. Our results may require further validation through a larger, multi-center clinical trial.
In conclusion, our prospective randomized controlled trial shows that biofeedback therapy seems to be effi cacious in the long-term management of patients with chronic constipation and dyssynergic defecation and is more likely to restore normal bowel function than standard therapy with laxatives.
